Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53).
- Citation:
- J Clin Oncol vol 25 (21) 3124-9
- Year:
- 2007
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- CA-25224, CA-35101, CA-35103, CA-35113, CA-35269, CA-35272, CA-35415, CA-35448, CA-37404, CA-37417, CA-52352, CA-60276, CA-63849
- Corr. Author:
- Authors:
- Steven E Schild James A Bonner Shauna Hillman Timothy F Kozelsky Antonio P G Vigliotti Randolph S Marks David L Graham Gamini S Soori John W Kugler Richard C Tenglin Donald B Wender Alex Adjei
- Networks:
- Study
- NCCTG-95-20-53
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Small Cell, Cisplatin, Combined Modality Therapy, Dose Fractionation, Dose-Response Relationship, Drug, Dose-Response Relationship, Radiation, Etoposide, Female, Humans, Immunohistochemistry, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Radiotherapy, High-Energy, Risk Assessment, Survival Analysis, Treatment Outcome